G&E Herbal Biotechnology Co., Ltd. (TPEX: 4911)
Taiwan
· Delayed Price · Currency is TWD 55.40
+0.50 (0.91%)
Nov 20, 2024, 1:30 PM CST
G&E Herbal Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 211.15 | 181.44 | 64.61 | 24.57 | 28.23 | 17.55 | Upgrade
|
| Revenue Growth (YoY) | 56.45% | 180.84% | 162.94% | -12.96% | 60.82% | 697.91% | Upgrade
|
| Cost of Revenue | 40.41 | 36.86 | 25.25 | 14.95 | 16.22 | 20.64 | Upgrade
|
| Gross Profit | 170.74 | 144.59 | 39.35 | 9.63 | 12.01 | -3.08 | Upgrade
|
| Selling, General & Admin | 41.71 | 39.3 | 19.48 | 16.65 | 14.77 | 14.2 | Upgrade
|
| Research & Development | 35.67 | 24.6 | 14.39 | 12.54 | 12.72 | 11.39 | Upgrade
|
| Operating Expenses | 77.37 | 63.9 | 33.87 | 29.19 | 27.49 | 25.6 | Upgrade
|
| Operating Income | 93.37 | 80.68 | 5.49 | -19.56 | -15.47 | -28.68 | Upgrade
|
| Interest Expense | -0.02 | -0 | - | - | - | - | Upgrade
|
| Interest & Investment Income | 5.54 | 4.4 | 0.6 | 0.52 | 0.61 | 0.89 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.03 | 0.01 | 1.06 | -0.39 | -0.02 | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.78 | 0.31 | 0.08 | 0 | 0.04 | 0.27 | Upgrade
|
| EBT Excluding Unusual Items | 99.69 | 85.4 | 7.23 | -19.43 | -14.84 | -27.52 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.01 | -0.01 | -0 | -0.02 | -0.01 | -0 | Upgrade
|
| Legal Settlements | 5.12 | 5.12 | - | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 1.22 | 1.79 | - | Upgrade
|
| Pretax Income | 104.8 | 90.5 | 7.23 | -18.22 | -13.06 | -27.52 | Upgrade
|
| Income Tax Expense | 20.98 | 18.1 | -0.15 | 1.66 | 1.24 | -4.15 | Upgrade
|
| Net Income | 83.82 | 72.4 | 7.38 | -19.88 | -14.3 | -23.37 | Upgrade
|
| Net Income to Common | 83.82 | 72.4 | 7.38 | -19.88 | -14.3 | -23.37 | Upgrade
|
| Net Income Growth | 78.16% | 880.90% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 59 | 59 | 59 | 59 | 59 | 59 | Upgrade
|
| Shares Outstanding (Diluted) | 59 | 59 | 59 | 59 | 59 | 59 | Upgrade
|
| Shares Change (YoY) | 0.10% | 0.08% | - | - | - | - | Upgrade
|
| EPS (Basic) | 1.42 | 1.23 | 0.13 | -0.34 | -0.24 | -0.40 | Upgrade
|
| EPS (Diluted) | 1.42 | 1.23 | 0.12 | -0.34 | -0.24 | -0.40 | Upgrade
|
| EPS Growth | 79.29% | 900.33% | - | - | - | - | Upgrade
|
| Free Cash Flow | 129.3 | 107.96 | 97.01 | -10.96 | -4.23 | -25.81 | Upgrade
|
| Free Cash Flow Per Share | 2.19 | 1.83 | 1.64 | -0.19 | -0.07 | -0.44 | Upgrade
|
| Dividend Per Share | 0.538 | 0.538 | - | - | - | - | Upgrade
|
| Gross Margin | 80.86% | 79.69% | 60.91% | 39.17% | 42.56% | -17.56% | Upgrade
|
| Operating Margin | 44.22% | 44.47% | 8.49% | -79.61% | -54.81% | -163.36% | Upgrade
|
| Profit Margin | 39.70% | 39.90% | 11.42% | -80.92% | -50.66% | -133.10% | Upgrade
|
| Free Cash Flow Margin | 61.24% | 59.50% | 150.15% | -44.61% | -14.98% | -147.05% | Upgrade
|
| EBITDA | 102.56 | 90.02 | 14.89 | -10.23 | -6.26 | -19.46 | Upgrade
|
| EBITDA Margin | 48.57% | 49.61% | 23.04% | -41.62% | -22.19% | -110.85% | Upgrade
|
| D&A For EBITDA | 9.2 | 9.33 | 9.4 | 9.33 | 9.21 | 9.22 | Upgrade
|
| EBIT | 93.37 | 80.68 | 5.49 | -19.56 | -15.47 | -28.68 | Upgrade
|
| EBIT Margin | 44.22% | 44.47% | 8.49% | -79.61% | -54.81% | -163.36% | Upgrade
|
| Effective Tax Rate | 20.02% | 20.00% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.